https://semalytix-shine.lovable.app/knowledge-base Field notes on Patient Experience Data from the Semalytix team. en https://semalytix-shine.lovable.app/knowledge-base/pomelo-the-standard-patient-voice-ai-was-waiting-for https://semalytix-shine.lovable.app/knowledge-base/pomelo-the-standard-patient-voice-ai-was-waiting-for Without scientifically sound frameworks, patient-voice AI is just louder guesswork. Why Semalytix co-authored the Pistoia Alliance's POMELO protocol, and how Atlas is engineered to it by design. Tue, 12 May 2026 00:00:00 GMT Philipp Cimiano Method https://semalytix-shine.lovable.app/knowledge-base/what-ped-really-is https://semalytix-shine.lovable.app/knowledge-base/what-ped-really-is PED is the unprompted, longitudinal voice of the patient. We unpack the difference between solicited PRO data and the messy, vital signal patients leave behind every day. Wed, 22 Apr 2026 00:00:00 GMT Janik Jaskolski Foundations https://semalytix-shine.lovable.app/knowledge-base/listening-at-scale https://semalytix-shine.lovable.app/knowledge-base/listening-at-scale How agentic pipelines collapse months of manual coding into hours, without flattening nuance. A walkthrough of our ingestion → signal → action loop. Wed, 11 Mar 2026 00:00:00 GMT Janik Jaskolski Method https://semalytix-shine.lovable.app/knowledge-base/adherence-drivers-2026 https://semalytix-shine.lovable.app/knowledge-base/adherence-drivers-2026 Cost, side effects, perceived efficacy and access. The proportions shift by therapy area, but the four are remarkably stable. Here's what the cohort data shows. Wed, 04 Feb 2026 00:00:00 GMT Philipp Cimiano Insights https://semalytix-shine.lovable.app/knowledge-base/claims-vs-conversation https://semalytix-shine.lovable.app/knowledge-base/claims-vs-conversation The structural reasons claims will never catch a discontinuation in time, and what teams should be measuring upstream of the refill gap. Mon, 19 Jan 2026 00:00:00 GMT Philipp Cimiano Method https://semalytix-shine.lovable.app/knowledge-base/regulators-on-ped https://semalytix-shine.lovable.app/knowledge-base/regulators-on-ped FDA, EMA and PMDA are all signalling. But the bar for inclusion in a label is specific: provenance, traceability, and a defensible cohort definition. Sun, 30 Nov 2025 00:00:00 GMT Janik Jaskolski Regulatory https://semalytix-shine.lovable.app/knowledge-base/tolerability-shifts-early https://semalytix-shine.lovable.app/knowledge-base/tolerability-shifts-early A pattern we've seen across three specialty therapies: patient vocabulary around side effects re-organises 4–8 weeks before the AE curve bends. Mon, 22 Sep 2025 00:00:00 GMT Philipp Cimiano Insights https://semalytix-shine.lovable.app/knowledge-base/fleets-not-models https://semalytix-shine.lovable.app/knowledge-base/fleets-not-models The case for narrow, accountable agents that hand off to each other, and why that architecture suits regulated pharma workflows better than a single oracle. Tue, 05 Aug 2025 00:00:00 GMT Janik Jaskolski Engineering https://semalytix-shine.lovable.app/knowledge-base/psp-routing-by-reason https://semalytix-shine.lovable.app/knowledge-base/psp-routing-by-reason A field study with a mid-size brand: when patient-services teams act on the cause of disengagement instead of a generic risk band, lift compounds. Tue, 17 Jun 2025 00:00:00 GMT Philipp Cimiano Case study https://semalytix-shine.lovable.app/knowledge-base/anonymisation-without-flattening https://semalytix-shine.lovable.app/knowledge-base/anonymisation-without-flattening How we strip PII while preserving the lived-experience texture clinicians and brand teams actually need to act. Pipelines, not promises. Fri, 02 May 2025 00:00:00 GMT Philipp Cimiano Foundations https://semalytix-shine.lovable.app/knowledge-base/the-silent-637b https://semalytix-shine.lovable.app/knowledge-base/the-silent-637b An updated estimate of the global non-adherence loss, broken down by therapy area, with the assumptions made transparent so teams can challenge them. Fri, 14 Mar 2025 00:00:00 GMT Janik Jaskolski Insights